Tarilian Laser Technologies (TLT) highlights 2 recent publications that have confirmed the importance of accurate continuous beat to beat blood pressure measurement
A key new publication from Chung S-C et al. (2018) Time spent at blood pressure target and the risk of death and cardiovascular diseases. PLoS ONE 13(9): e0202359 has revealed the dramatic effect of time spent in blood pressure target ranges. This study examined a population-based cohort of 169,082 individuals with newly identified high blood pressure who were free of cardiovascular disease from January 1997 to March 2010. The analysis included 1.64 million clinical blood pressure readings to calculate the TIme at TaRgEt ( or abbreviated to TITRE) based on current target blood pressure levels. They found that compared to people with a 0% TITRE – ie who were never in the target control range, patients with a TITRE of 3–5.9 months ( ie were in range for 3 to 6 months) had 75% lower odds of the composite risk of cardiovascular death, myocardial infarction and stroke.
A new Study just published in the New England Journal of Medicine from Professor Roth on 20th December 2018 reveals that bbout one-quarter of adults in the world will experience a stroke in their lifetime, according to new estimates from the Global Burden of Disease Study (GBDS). And furthermore this risk has increased in the past 2 decades.
The GBDS 2016 study analysis examined epidemiologic data to assess health loss from 328 diseases across 195 countries and territories from 1990 through 2016. Cumulative lifetime incidence of a first stroke—including ischemic or hemorrhagic strokes—among adults 25 or older was assessed.
After adjusting for competing causes of death, the Study found 24.9 percent of people from the age of 25 onward could be expected to have a stroke in their remaining lifetimes. That 2016 proportion is up from the 22.8 percent estimate from 1990, representing a relative increase of 8.9 percent.
Other interesting findings from the study include:
The regions with the highest lifetime risks of stroke were:
- East Asia (38.8 percent), Central Europe (31.7 percent) and Eastern Europe (31.6 percent)
- Among countries, China had the highest estimated risk at 39.3 percent.
Commenting on these studies, Dr. Sandeep Shah, CEO of Tarilian Laser Technologies Ltd and Senior Clinical Research Fellow at The Barts Heart Centre in London stated : “ These new studies reveal the dramatic importance of reliable frequent remote monitoring of continuous beat to beat blood pressure. All the recent updated guidelines on the management of blood pressure have focussed on the need for better target control and keeping patients at lower optimal blood pressure ranges. With the unique TLT technology, patients and doctors can reliably and easily measure beat to beat blood pressure and thus evaluate time with target range. Furthermore, it is now clear that this makes a big difference to clinical outcomes – clearly reducing risk of events such as stroke, heart attacks and even death! This is a major breakthrough in Medicine ! “
About Tarilian Laser Technologies Limited
Tarilian Laser Technologies Limited (TLT) is a Medtech Company based in Welwyn Garden City, Hertfordshire, UK (Head Office and Labs), as well as having its TLT-Vicardio® Commercial office in Leeds, UK and also its US operations office in Minneapolis, Minnesota, USA. TLT is also opening a new regulatory office in Singapore. Our main clinical centre is The Barts Heart Centre in London, Europe’s largest cardiovascular research centre.
Please see: www.tarilian.co.uk to directly access the 30-minute Bloomberg World-Wide Business Interview that summarises Tarilian Laser Technologies.
TLT is an advanced Medtech SME and is 13485(2016) registered with solid competencies in medical engineering, research & development, clinical trials, regulatory affairs and commercialisation. TLT has developed a novel optical platform based on its internal proprietary patented opto-electronic micro-sensor for full haemodynamic profiling including an ability to generate beat to beat blood pressure, compliance data, cardiac output and regional blood flow and blood pressure. A unique aspect of the TLT Sapphire sensor is that no energy enters the body at all – hence it is truly NON-invasive and also does not require any compression/cuff and or require any calibration in any manner. You simply apply the sensor on the body and it works instantly delivering continuous beat to beat haemodynamic data. The technology has already won many awards and TLT has continued with a number of additional break-throughs in sensor development- and now is planning a series of product launches from Early 2019, to begin the introduction of the technology into a number of international Medtech and consumer wearable markets. Unlike other attempts at cuffless technology over the past 50 years – which have relied on invasion of energy into the body and reflection back to a detector – which is problematic and highly inaccurate – the TLT team have broken a major barrier in sensor technology and developed a high-fidelity system that accurately and effectively generates the most important surface physiological parameters that determine blood pressure. This technology which has over 49 patents is a paradigm shift and will create a whole new series of applications in consumer and hospital care.
Commenting on an impressive 2018, Dr Shah, CEO of TLT and Senior Clinical Fellow at The Barts Heart Centre, Europe’s leading Cardiovascular Centre stated: “ TLT has successfully won a whole series of awards and acclaim in 2018. Furthermore, we are pleased to announce that TLT has been named as a Finalist in The 2019 10th IOT/WT Innovation World Cup® in the Top Innovators Healthcare Category. We are now eager to examine the powerful potential of the TLT technology across all clinical trial domains.”
Contact: Dr Sandeep Shah (CEO)
Tarilian Laser Technologies Ltd
Phone: 01707 332 883